Bristol-Myers Squibb is running a rigorous Phase 2/3 clinical trial on ozanimod, aiming to help children with moderate to severe ulcerative colitis who haven’t responded to conventional treatments.

The stock's rise snapped a four-day losing streak.

In total, there are about 50 student volunteers, along with an additional 350 volunteers registered to work on an ad hoc ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

The market, which was valued at $0.85 billion in 2024, is projected to grow to $0.91 billion in 2025, representing a compound annual growth rate CAGR of 7.2%. The growth during this historic period ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan ...

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April ...